BREAST CANCER

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

Kathy S. Albain, MD, discusses staging versus biology in breast cancer.

Minetta Liu, MD, discusses the limitations of radiology in the treatment of patients with metastatic breast cancer.

Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.

Elizabeth Mittendorf, MD, PhD, discusses the use of peptide vaccines for the treatment of breast cancer.

Aditya Bardia, MD, MPH, discusses recent advancements in the field of breast cancer.

Updated recommendations for HER2 testing in breast cancer have been released by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP).

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.

Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses the overdiagnosis of breast cancer.

The FDA has approved pertuzumab (Perjeta), the first neoadjuvant treatment for patients with breast cancer.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.

A subgroup analysis showed that certain patients with breast cancer may benefit more from eribulin, and quality of life (QoL) data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.

Debu Tripathy, MD, discusses targeting HER2 in breast cancer.

Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses the background and results of a study looking at crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).

It has long been recognized that many breast tumors in postmenopausal women are hormone-dependent and that hormonal manipulation can alter the natural history of the disease. Learn more about the mechanism of action of fulvestrant (Faslodex).

New approaches to treating women with advanced ER+ breast cancer are in development, which includes both hormone therapy and combinations with targeted agents. The continuing goal is to understand disease biology and individualize treatment regimens to increase survival.

Jonathan D. Herman, MD, obstetrician and gynecologist at Hofstra North Shore - LIJ Medical School, discusses the findings from a survey looking at breast cancer risk perception.

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer (TNBC), but recent studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Sandra Swain, MD, discusses pregnancy-related breast cancer.

The human epidermal growth factor receptors (known as the HER family) play a pivotal role in transmitting signals that regulate cell growth and survival.

Meredith C. Henderson, PhD, Head, R&D, Provista Diagnostics, describes the dtectDx Breast test.

The FDA’s Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab (Perjeta) in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Studies presented at the 2013 Breast Cancer Symposium investigated the efficacy and safety of various approaches to the treatment of HER2-positive breast cancer.

A pair of studies from the 2013 Breast Cancer Symposium delivered promising and preliminary news about the microtubule inhibitor eribulin mesylate.